Muhammad Hamdan, MD
Hematology & Oncology · Lansing, MINPI 1528091980
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,441 of the $1,811 with a category attached, or 79.6%. It is spread thinly across 28 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $753 and has fallen 90.4% since, to $72 in 2025. That places this record below the midpoint for hematology & oncology clinicians in MI, where the typical reported total is $1,604.
Across 86 payments — averaging $21.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$243
- AstraZeneca$222
- Johnson & Johnson$145
- Bristol Myers Squibb$134
- Amgen$127
- Pfizer$110
- plus $829 from 22 others
Across 1 payment — averaging $55,714 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$56K
What the payments were for
- Food & beverage$1,44180%
- Education$37020%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 13 | $243 |
| AstraZeneca(2 entities) | 3 | $222 |
| Johnson & Johnson(2 entities) | 4 | $145 |
| Bristol Myers Squibb | 6 | $134 |
| Amgen | 8 | $127 |
| Pfizer | 6 | $110 |
| AbbVie | 4 | $102 |
| Daiichi Sankyo Inc. | 3 | $74 |
| Genentech USA, Inc. | 5 | $73 |
| Gilead(2 entities) | 5 | $65 |
| Foundation Medicine, Inc. | 2 | $62 |
| Sanofi | 3 | $59 |
| E.r. Squibb & Sons, L.L.C. | 3 | $49 |
| Lilly USA, LLC | 3 | $46 |
| Array Biopharma Inc | 2 | $42 |
| Merck | 3 | $41 |
| Astellas Pharma US Inc | 2 | $38 |
| Servier Pharmaceuticals LLC | 1 | $22 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $19 |
| EMD Serono, Inc. | 1 | $19 |
| Pharmaessentia USA Corporation | 1 | $18 |
| Agios Pharmaceuticals, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $15 |
| GSK | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
| Clovis Oncology, Inc. | 1 | $13 |
| Puma Biotechnology, Inc. | 1 | $11 |
How this compares
$1,811 in reported general payments places this provider in the 50th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 72 | $1,044,934 |
| JakafiRuxolitinib Phosphate | 74 | $1,001,642 |
| XtandiEnzalutamide | 54 | $714,111 |
| VenclextaVenetoclax | 65 | $445,048 |
| RevlimidLenalidomide | 28 | $429,979 |
| WeliregBelzutifan | 13 | $372,665 |
| ImbruvicaIbrutinib | 21 | $343,602 |
| Lenalidomide | 24 | $313,363 |
| XermeloTelotristat Etiprate | 26 | $243,349 |
| BosulifBosutinib | 14 | $179,159 |
| EliquisApixaban | 186 | $146,359 |
| Everolimus | 18 | $137,603 |
| XareltoRivaroxaban | 92 | $80,804 |
| Abiraterone Acetate | 38 | $77,658 |
| LapatinibLapatinib Ditosylate | 12 | $59,675 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada, Xarelto | $145 | $1,125,737164 claims |
| Astellas Pharma US IncXtandi | $38 | $714,11154 claims |
| AbbVieVenclexta, Creon | $102 | $499,53886 claims |
| Bristol Myers SquibbRevlimid | $134 | $429,97928 claims |
| MerckWelireg | $41 | $372,66513 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $19 | $343,60221 claims |
| PfizerBosulif, Eliquis | $110 | $325,517200 claims |
| Lilly USA, LLCOlanzapine | $46 | $43191 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 282 hematology & oncology providers in Michigan.
Other hematology & oncology in Lansing
- Gordon SrkalovicLansing$167K
- Brittani ThomasLansing$7K
- Faisal MusaDearborn$976K
- Mohammed Al HallakDetroit$644K
- Daniel LebovicGrosse Pointe Woods$352K
- Sreenivasa ChandanaGrand Rapids$305K
- Mohammad ChistiTroy$180K
- Jeffrey ZonderDetroit$88K
- Madan AroraFlint$84K
- Hadeel AssadDetroit$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.